SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
11 Oct 2020
11 Oct 2020
Historique:
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
15
10
2020
Statut:
epublish
Résumé
COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared by the World Health Organization a global public health emergency. Among the severe outbreaks across South America, Uruguay has become known for curtailing SARS-CoV-2 exceptionally well. To understand the SARS-CoV-2 introductions, local transmissions, and associations with genomic and clinical parameters in Uruguay, we sequenced the viral genomes of 44 outpatients and inpatients in a private healthcare system in its capital, Montevideo, from March to May 2020. We performed a phylogeographic analysis using sequences from our cohort and other studies that indicate a minimum of 23 independent introductions into Uruguay, resulting in five major transmission clusters. Our data suggest that most introductions resulting in chains of transmission originate from other South American countries, with the earliest seeding of the virus in late February 2020, weeks before the borders were closed to all non-citizens and a partial lockdown implemented. Genetic analyses suggest a dominance of S and G clades (G, GH, GR) that make up >90% of the viral strains in our study. In our cohort, lethal outcome of SARS-CoV-2 infection significantly correlated with arterial hypertension, kidney failure, and ICU admission (FDR < 0.01), but not with any mutation in a structural or non-structural protein, such as the spike D614G mutation. Our study contributes genetic, phylodynamic, and clinical correlation data about the exceptionally well-curbed SARS-CoV-2 outbreak in Uruguay, which furthers the understanding of disease patterns and regional aspects of the pandemic in Latin America.
Identifiants
pubmed: 33052352
doi: 10.1101/2020.10.08.20208546
pmc: PMC7553156
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122953
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Clin Infect Dis. 2020 Aug 07;:
pubmed: 32766823
J Biomed Sci. 2020 Jun 7;27(1):73
pubmed: 32507105
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
J Transl Med. 2020 Apr 22;18(1):179
pubmed: 32321524
Osong Public Health Res Perspect. 2020 Jun;11(3):101-111
pubmed: 32528815
J Hum Genet. 2020 Dec;65(12):1075-1082
pubmed: 32699345
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
Virus Res. 2020 Oct 2;287:198098
pubmed: 32687861
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Science. 2020 Jul 17;369(6501):297-301
pubmed: 32471856
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Int J Clin Pract. 2020 Aug;74(8):e13525
pubmed: 32374903
Science. 2020 Sep 4;369(6508):1255-1260
pubmed: 32703910
Mol Biol Evol. 2010 Aug;27(8):1877-85
pubmed: 20203288
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211